@article{d8a9bcba89ab41f984e3ea87fcde09cd,
title = "A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment",
abstract = "Introduction: Recent studies suggest that Alzheimer's disease (AD) biomarker disclosure has no discernable psychological impact on cognitively healthy persons. Far less is known about how such results affect symptomatic individuals and their caregivers. Methods: Randomized controlled trial of 82 mild cognitive impairment (MCI) patient and caregiver dyads (total n = 164) to determine the effect of receiving amyloid positron emission tomography results on understanding of, and perceived efficacy to cope with, MCI over 52 weeks of follow-up. Results: Gains in the primary outcomes were not consistently observed. Amyloid negative patients reported greater perceived ambiguity regarding MCI at follow-up, while moderate and sustained emotional distress was observed in patients, and to a lesser extent, caregivers, of those who were amyloid positive. There was no corresponding increase in depressive symptoms. Discussion: These findings point to the possibility that both MCI patients and caregivers may need emotional support after the disclosure of amyloid scan results.",
keywords = "amyloid positron emission tomography, biomarker disclosure, caregiving, ethics, mild cognitive impairment",
author = "Lingler, {Jennifer H.} and Sereika, {Susan M.} and Butters, {Meryl A.} and Cohen, {Ann D.} and Klunk, {William E.} and Knox, {Melissa L.} and Eric McDade and Nadkarni, {Neelesh K.} and Roberts, {J. Scott} and Tamres, {Lisa K.} and Lopez, {Oscar L.}",
note = "Funding Information: The authors gratefully acknowledge the participants who volunteered for this research. We also thank Drs. Meghan Mattos and Jonna Morris and Ms. Sarah Goldberg for their efforts as pre-test counselors. This study was supported by NIH/NIA R01AG046906-01, NIH/NIA, P50 AG05133, and NIH/NIA P30 AG053760. Florbetapir F 18 Injection doses in this study are supplied at no cost by Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lily, Inc. The week-4 follow-up data reported in this manuscript were first presented at the 2019 Alzheimer's Association International Conference. Funding Information: The authors gratefully acknowledge the participants who volunteered for this research. We also thank Drs. Meghan Mattos and Jonna Morris and Ms. Sarah Goldberg for their efforts as pre‐test counselors. This study was supported by NIH/NIA R01AG046906‐01, NIH/NIA, P50 AG05133, and NIH/NIA P30 AG053760. Florbetapir F 18 Injection doses in this study are supplied at no cost by Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lily, Inc. The week‐4 follow‐up data reported in this manuscript were first presented at the 2019 Alzheimer's Association International Conference. Publisher Copyright: {\textcopyright} 2020 the Alzheimer's Association",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/alz.12129",
language = "English",
volume = "16",
pages = "1330--1337",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
number = "9",
}